Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global HIV Rapid Test Kits Market - Outlook and Forecast 2023-2028
The market size of global HIV rapid test kits was valued at USD 1.437 billion in 2022 and is projected to reach USD 1.68 billion by 2028, with a CAGR of 2.70%. In the United States, HIV testing plays a vital role in prevention and management efforts. As awareness about HIV infection continues to grow rapidly in the country, there has been an increasing demand for HIV self-testing. In recent years, routine medical checkups have included HIV tests for a significant portion of the population, leading to greater knowledge about HIV testing and care, and driving market growth.
HIV, a viral infection that attacks the immune system, currently lacks effective care treatment worldwide and can progress to acquired immunodeficiency syndrome (AIDS). Globally, over 38.4 million people live with HIV infection, with Africa having the highest patient population. HIV remains one of the leading causes of death worldwide. The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) are major organizations focused on increasing awareness about HIV, HIV infection, and preventive measures. By 2030, these organizations aim to reduce the global HIV burden by approximately 90%. Many countries have joined these initiatives to improve their national HIV status. HIV self-testing (HIVST) is a key strategy advocated by WHO and UNAIDS to address the HIV burden, leading to increased demand for HIV rapid test kits.
|No. of Pages||
USD 1.4 billion in 2021
Technology, Sample Type, Distribution Channels, and Geography
|No. of Companies Mentioned||
Some countries in the Asia-Pacific (APAC) region lack manufacturing facilities and rely heavily on imports for HIV rapid test kits. For instance, Indonesia imports HIV rapid test kits from countries like India, China, and Sweden, resulting in lower competition for market players. The WHO has prioritized the fast-tracking of HIV self-testing implementation and scale-up in the APAC region to reduce infection rates. Several APAC countries have initiated HIVST pilot projects, which are expected to drive the demand for HIV rapid test kits and accelerate market growth in the region.
Fourth-generation rapid test kits have gained popularity in recent years due to their superior accuracy and reliability in screening acute HIV presence. These tests can detect HIV more quickly and accurately compared to previous-generation technologies. Early detection allows individuals to seek treatment sooner and potentially prevent the spread of infection. OraSure Technologies, a leading player in the HIV rapid test kit market, has obtained approval for a home test kit called OraQuick In-Home HIV Test, which provides results within 20 to 40 minutes.
UNAIDS and WHO are collaborating to prevent HIV transmission. They have implemented various strategies worldwide to promote HIV self-testing (HIVST) and gain a better understanding of the global burden of HIV/AIDS. Regions such as Eastern and Southern Africa, as well as Western and Central Europe & North America, have implemented several HIVST policies that contribute to the growth opportunities in the HIV rapid test kits market. Increasing acceptance of HIVST has led to greater knowledge and awareness about HIV among people, resulting in a higher demand for easy HIV testing.
The COVID-19 pandemic has caused disruptions in HIV diagnosis and treatment services, impacting progress towards the UNAIDS 2030 target. However, the pandemic has also accelerated the adoption of digital tools in healthcare services, including HIV care management. The application of digital tools in HIV management is on the rise, which is expected to fuel the HIV rapid test kits market. According to research published in The Lancet, there has been an increasing adoption and innovation of digital HIV self-testing tools, with website-based innovations gaining popularity.
In 2020, approximately 15 million people acquired HIV, and by 2022, it was estimated that over 38 million people would be living with HIV. This further increases the demand for HIV testing and the use of self-test kits as preventive measures. High-infection regions such as Africa, Europe, and Asian countries are witnessing a year-on-year increase in demand for HIV testing, driving the application of HIV rapid test kits and stimulating market growth.
Significant progress has been made by most countries in reducing the burden of HIV through efforts led by UNAIDS and WHO. By 2025, it is expected that around 95% of people living with HIV globally will be aware of their HIV status. Moreover, there is a rapid increase in HIV awareness among both infected and non-infected individuals in developed and developing countries. Developed countries have implemented various programs supported by governments and health authorities to raise awareness about HIV self-testing solutions. The increasing availability of HIV rapid test kits through health authorities and vendors, along with the growing acceptance of self-testing kits for managing HIV, are simultaneously contributing to the growth of the HIV rapid test kits market.
The market is segmented based on various factors, including technology, sample type, distribution channels, and geography.
Segmentation by Technology
Lateral Flow Immunoassay
Segmentation by Sample Type
Segmentation by Distribution Channels
Segmentation by Geography
North America – US, Canada
Europe – France, Italy, Ukraine, Portugal, Russia
APAC – China, India, Indonesia, Thailand, Vietnam
Latin America – Brazil, Mexico, Columbia
Middle East & Africa – South Africa, Mozambique, Kenya, Nigeria, Tanzania,
The global market for HIV rapid test kits can be categorized based on technology into two segments: lateral flow immunoassay and immunofixation. In 2021, the lateral flow immunoassay segment held a significant market share of 78.25%. This technology is widely used in the development of HIV rapid test kits, as it offers accurate and advantageous results. One of the main reasons for the growing preference for HIV rapid test kits is their ability to provide immediate results. This enables healthcare professionals to make timely treatment plans and take preventive measures to reduce the spread of the disease.
Among the different sample types, blood samples accounted for the majority market share of 63.46% in the global HIV rapid test kits market. Blood sample-based HIV rapid test kits are highly recommended by medical professionals due to their high concentration of HIV antibodies. Healthcare providers prefer using blood samples such as plasma, serum, or dried blood spots (DBS) for HIV rapid testing because they contain higher concentrations of HIV antibodies compared to oral (saliva) samples. These test kits detect antibodies using a small drop of blood from the fingertip. Apart from individual use, healthcare settings like clinical laboratories, research centers, and community-based organizations also rely on HIV rapid test kits, further driving the growth of the blood sample segment.
In terms of distribution channels, offline sales dominate the global HIV rapid test kits market with a market share of 66.70%. Offline sales channels include medical shops, pharmacies, hospitals, clinics, associated pharmacies, and pharma retailers. In low- and middle-income countries (LMICs), offline sales channels, particularly medical pharmacies, serve as the primary point of access for HIV testing. The convenience and easy availability of HIV rapid test kits drive significant sales through offline channels. Drug shops, which are often the first point of care for medical solutions in LMICs, offer an alternative to facility-based HIV testing and counseling. Consumers prefer these offline stores to avoid long waiting times and potential clinical staff fees.
North America holds the largest market share in the global HIV rapid test kits market, accounting for 31.06%. The region’s market growth is driven by a higher prevalence of HIV and increased awareness among key patient populations. Government support and funding for HIV management and preventive measures also contribute to the significant market growth in North America. In 2022, over 3.8 million people in North America were estimated to be living with HIV. The United States has particularly high awareness about HIV self-testing, while Canada shows progressive growth in this area.
The European market for HIV rapid test kits was valued at USD 158.8 million in 2022. East Europe is experiencing a continuous increase in new HIV diagnoses, although from a lower base in Central Europe. Western Europe, on the other hand, has stable but increasing numbers of new HIV diagnoses among transgender individuals and men who have sex with men (MSM) in most regions.
The global market for HIV rapid test kits is populated by numerous global, regional, and domestic players who offer a wide range of HIV rapid test kit products. Certain global market players have achieved significant industry penetration through extensive distribution networks and effective business strategies. Additionally, some companies collaborate with organizations such as the World Health Organization (WHO) and UNAIDS to promote the adoption of HIV self-testing by supporting HIV rapid test kits. In 2022, WHO, in partnership with the Clinton Health Access Initiative (CHAI), Wondfo Biotech Company, and MedAccess, made HIV self-test kits available for only USD 1 in the public sector of low- and middle-income countries (LMICs). This initiative is expected to intensify competition among leading market players. The growth strategies pursued by these leading players serve as barriers to entry for small and emerging market players.
Abbott, Bio-Rad Laboratories, BIOMÉRIEUX, Chembio Diagnostics, and OraSure Technologies are key companies operating in the global HIV rapid test kits market. The competitive landscape varies across different countries. In North America, competition in the HIV rapid test kits market is moderate due to stringent regulations and guidelines governing the approval of such kits. The United States, for example, has approved and made over-the-counter (OTC) HIV rapid test kits available. In some European countries, healthcare facilities provide free distribution of HIV self-test kits to individuals as a measure to curb the spread of infections.
Key companies profiled in this report include Abbott, Bio-Rad Laboratories, BIOMÉRIEUX, Chembio Diagnostics, OraSure Technologies, Atomo Diagnostics, AccuBioTech, bioLytical Laboratories, Biosynex, Cupid Limited, DIALAB, HUMAN, INTEC, J. Mitra & Co, Meril Life Sciences, MP Biomedicals, Medsource Ozone Biomedicals, Nanjing Synthgene Medical Technology, Premier Medical, SD Biosensor, KHB (Shanghai Kehua Bio-Engineering co., Ltd.), Türklab A.S., Trinity Biotech, Wantai BioPharma, Wondfo.
Key Questions Answered
What is the market size of HIV rapid test kits?
The market for HIV rapid test kits had a valuation of USD 1.43 billion in 2022 and is projected to reach USD 1.68 billion by 2028.
What is the growth rate of the HIV rapid test kits market?
The HIV rapid test kits market is growing at a compound annual growth rate (CAGR) of 2.70% from 2022 to 2028.
Which region has the largest share in the global HIV rapid test kits market?
North America holds the most significant market share in the global HIV rapid test kits market, accounting for 31.06%. This dominance is attributed to the higher acceptance of HIV rapid tests among people in the region.
What are the emerging trends in the HIV rapid test kits market?
The emerging trends in the HIV rapid test kits market include increasing demand for next-generation HIV rapid test kits, growing acceptance of HIV self-testing facilitated by government policies, and the integration of digital support in HIV self-testing.
Which companies are key players in the global HIV rapid test kits market?
The key companies in the global HIV rapid test kits market are Abbott, Bio-Rad Laboratories, BIOMÉRIEUX, Chembio Diagnostics, and OraSure Technologies.